Nitatsid-Darnitsa

General characteristics. Structure:

Active ingredients: 1 g of ointment contains streptocide 50 mg, Nitazolum of 25 mg;

excipients: propylene glycol, macrogoal 400, half-oxameasures.

Pharmacological properties:

Nitatsid®-Darnitsa ointment contains in the structure streptocide – streptocide and antibacterial agent Aminitrazolum – Nitazolum, thanks to their combination ointment        has antimicrobic effect on gram-positive and gram-negative, aerobic and anaerobic, spore-forming and asporogenic microflora: staphylococcus, streptococci, pyocyanic and intestinal sticks, a klebsiyella, clostridiums, bacteroids, peptokokk and other microorganisms in the form of monocultures and microbic associations, including hospital strains of bacteria with polyresistance to other chemotherapeutic drugs. Drug is less effective in relation to a protea.

Nitatsid®-Darnitsa ointment shows antiinflammatory action. The ointment basis has giperosmolyarny properties thanks to what promotes dehumidification of a wound and occludes is purulent - necrotic masses, than clears a wound. The macrogoal of the 400th ointment basis facilitates penetration of active ingredients into the fabrics surrounding a wound and thus makes impact on glubinno the located activators, affecting preventively development of consecutive infection.

At topical administration has no local irritative and allergenic effect, does not damage granulyatsionny fabric and viable cells of skin.

The special physical and chemical characteristics of an ointment basis (raised osmotic activity) which are in a basis high-molecular polymers with sorption properties hold active components of ointment on site of drawing and their diffusions in a system blood stream interfere. After putting ointment its remains with sorbed it is purulent - necrotic masses are removed at the next bandaging.

Indications to use:

Nitatsid®-Darnitsa ointment is appointed the adult for treatment of the wounds complicated by an infection, and also for treatment of a purulent inflammation of soft tissues of various localization (amputating stumps of extremities, trophic ulcers, decubituses, postoperative wounds, fistulas, phlegmons, abscesses), including in maxillofacial area after their surgical treatment, and also for treatment of the inflammatory diseases of skin complicated by a pyoderma, superficial and deep burns of the II-IV degree.

Route of administration and doses:

Nitatsid®-Darnitsa ointment is applied locally adult. After standard processing of wounds    and burns ointment is applied directly on the struck surface, then apply a sterile gauze bandage or ointment apply on a dressing material, and then on   a wound. Densely fill with the tampons impregnated with ointment cavities of purulent wounds after their surgical treatment, and gauze turundas with ointment enter into the fistular courses.

At treatment of purulent wounds ointment is applied 1 time a day, at treatment of burns – daily or 2-3 times a week depending on quantity of purulent discharges. The amount of ointment depends on the area of a wound surface and degree of purulent exudation and can reach at adult 400 g. Duration of treatment is defined by dynamics of clarification of wounds from is purulent - necrotic masses, expressiveness of stopping of inflammatory process and tightening of wounds granulyatsionny fabric. At inflammatory diseases in    dermatology ointment is applied on skin a thin layer by 1-2 times a day or on a gauze   bandage with the subsequent application on an erosive and ulcer surface within 1-2 weeks. In the presence on ulcers and erosion of purulent discharges they are previously cleared solutions: 0,01% of a miramistin, Furacilin 1:5000, 3 of % of peroxide of hydrogen or 1-2% of boric acid.

Features of use:

Use during pregnancy or feeding by a breast.

Drug is contraindicated to use during pregnancy or feeding by a breast.

Ability to influence speed of response at control of motor transport or work with other mechanisms. Does not influence.

Children.

Safety and efficiency of use of Nitatsid®-Darnitsa ointment for children are not established therefore patients of this age category are not recommended to use drug.

Side effects:

From skin: local hypostases, peeling, reddening, itch, rash, contact dermatitis, small tortoiseshell, moknuty, Quincke's edema.

In some cases at treatment of burns and trophic ulcers there can be a burning sensation and morbidities which pass independently or demand pretreatment of a wound surface solution of local anesthetic.

At prolonged use of high doses – systemic action: the complicated breath, compression in a breast, fever, a fever, a headache, a pharyngalgia, dyspepsia, a leukopenia, an agranulocytosis, nausea, vomiting, a dysuria, a crystalluria.

Interaction with other medicines:

Efficiency of treatment by Nitatsid®-Darnitsa ointment can increase at co-administration of system antibiotics and antimicrobic means.

Efficiency of treatment by Nitatsid®-Darnitsa ointment decreases at co-administration of other ointments containing sorbents.

At use of Nitatsid®-Darnitsa ointment it is undesirable to use such drugs as digitoxin, Acidum hydrochloricum, caffeine, a phenylephine hydrochloride, phenobarbital, Adrenalinum hydrochloricum.

Contraindications:

Hypersensitivity to streptocide, Nitazolum or to any of auxiliary components of drug. Pregnancy, feeding period breast.

Necessary security measures at use.

Effect of ointment partially weakens at its drawing on wounds with high content is purulent - necrotic masses. Therefore it is better to apply ointment on wounds after washing them solutions of antiseptic agents.

At emergence of allergic reaction in a site of application of ointment it is necessary to stop drug use.

The premature termination of treatment by drug can cause development of microorganisms, steady against streptocides.

During therapy it is recommended to drink many alkaline drinks.

Overdose:

It is improbable. When putting ointment on extensive wound surfaces the possibility of partial hit of active components of ointment in a system blood stream in the quantities not capable to cause acute poisoning is not excluded.

Strengthening of manifestations of side reactions is possible.

Storage conditions:

Period of validity. 2 years. To store in the place, unavailable to children, in original packaging at a temperature not above 15 °C.

Issue conditions:

Without recipe

Packaging:

On 15 g in a tuba, on 1 tuba in a pack; on 500 g in banks.